Induction in Pancreas Transplantation: T-cell Depletion Versus IL-2 Receptor Blockade

被引:7
作者
Aziz, Fahad [1 ]
Parajuli, Sandesh [1 ]
Kaufman, Dixon [2 ]
Odorico, Jon [2 ]
Mandelbrot, Didier [1 ]
机构
[1] Univ Wisconsin, Div Nephrol, Dept Med, Sch Med & Publ Hlth, 1685 Highland Ave, Madison, WI 53705 USA
[2] Univ Wisconsin, Div Transplant Surg, Sch Med & Publ Hlth, Madison, WI 53705 USA
关键词
KIDNEY TRANSPLANTATION; BASILIXIMAB INDUCTION; ALEMTUZUMAB; REJECTION; THERAPY; MULTICENTER;
D O I
10.1097/TXD.0000000000001402
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. There is limited data exist on relative outcomes with T-depletion versus IL-2 receptor (IL2R) blockade induction in pancreas transplantation. Methods. We analyzed all patients who underwent simultaneous pancreas-kidney or pancreas transplant alone at our institution between January 1, 2011, and December 31, 2019. Results. Of 417 pancreas transplant recipients, 291 received induction with a T-depleting agent and 126 received induction with an IL2R blocker. No difference was detected in pancreas allograft death-censored (P=0.7) or uncensored (P=0.5) survival. Although pancreas rejection was more common overall (P=0.03), this difference was no longer present in recipients at low immunologic risk (P=0.08). Cytomegalovirus and bacterial infections were significantly more common in the patients who received T-cell depleting agents for induction (21% versus 11%, P=0.03; 34% versus 23%, P=0.04, respectively). On multivariate analysis, history of pancreas rejection (Hazard ratio (HR)= 4.7, P=0.0001; 95% Confidence interval (CI), 2.16-10.12) and higher calculated panel reactive antibodies (HR =1.01, P=0.04; 95% CI, 1.0002-1.02) were associated with increased risk of pancreas allograft failure, but choice of induction was not (HR=0.64, P=0.3; 95% CI, 0.27-1.51). Further, on multivariate analysis, Cytomegalovirus infection was associated with increased risk of pancreas allograft rejection (HR =1.78, P=0.01; 95% CI, 1.11-2.87), but choice of induction was not (HR =0.84, P=0.46; 95% CI, 0.54-1.32). Similarly, bacterial infection was associated with increased risk of patient death (HR = 2.94, P=0.04; 95% CI, 1.03-8.32). Conclusion. Our data suggest that IL-2 receptor blockade may be a reasonable choice of induction for pancreas transplant recipients at low immunologic risk.
引用
收藏
页数:7
相关论文
共 16 条
[1]   Alloimmunity in pancreas transplantation [J].
Aziz, Fahad ;
Mandelbrot, Didier ;
Parajuli, Sandesh ;
Al-Qaoud, Talal ;
Redfield, Robert ;
Kaufman, Dixon ;
Odorico, Jon S. .
CURRENT OPINION IN ORGAN TRANSPLANTATION, 2020, 25 (04) :322-328
[2]   Thymoglobulin Versus Basiliximab Induction Therapy for Simultaneous Kidney-Pancreas Transplantation: Impact on Rejection, Graft Function, and Long-Term Outcome [J].
Bazerbachi, Fateh ;
Selzner, Markus ;
Boehnert, Markus U. ;
Marquez, Max A. ;
Norgate, Andrea ;
McGilvray, Ian D. ;
Schiff, Jeffrey ;
Cattral, Mark S. .
TRANSPLANTATION, 2011, 92 (09) :1039-1043
[3]   The beneficial effects of pancreas transplant alone on diabetic nephropathy [J].
Coppelli, A ;
Rizzo, G ;
Giannarelli, R ;
Mosca, F ;
Vistoli, F ;
Boggi, U ;
Del Prato, S ;
Marchetti, P .
DIABETES CARE, 2005, 28 (06) :1366-1370
[4]   Acute Pancreas Allograft Rejection Is Associated With Increased Risk of Graft Failure in Pancreas Transplantation [J].
Dong, M. ;
Parsaik, A. K. ;
Kremers, W. ;
Sun, A. ;
Dean, P. ;
Prieto, M. ;
Cosio, F. G. ;
Gandhi, M. J. ;
Zhang, L. ;
Smyrk, T. C. ;
Stegall, M. D. ;
Kudva, Y. C. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (04) :1019-1025
[5]  
Gross CR, 1998, CLIN TRANSPLANT, V12, P351
[6]   The current state of pancreas transplantation [J].
Gruessner, Rainer W. G. ;
Gruessner, Angelika C. .
NATURE REVIEWS ENDOCRINOLOGY, 2013, 9 (09) :555-562
[7]   Chronic rejection: The next major challenge for pancreas transplant recipients [J].
Humar, A ;
Khwaja, K ;
Ramcharan, T ;
Asolati, M ;
Kandaswamy, R ;
Gruessner, RWG ;
Sutherland, DER ;
Gruessner, AC .
TRANSPLANTATION, 2003, 76 (06) :918-923
[8]   Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - Long-term results [J].
Kaufman, DB ;
Leventhal, JR ;
Gallon, LG ;
Parker, MA .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (02) :331-339
[9]   Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation [J].
Kaufman, DB ;
Burke, GW ;
Bruce, DS ;
Johnson, CP ;
Gaber, AO ;
Sutherland, DER ;
Merion, RM ;
Gruber, SA ;
Schweitzer, E ;
Leone, JP ;
Marsh, CL ;
Alfrey, E ;
Concepcion, W ;
Stegall, MD ;
Schulak, JA ;
Gores, PF ;
Benedetti, E ;
Smith, C ;
Henning, AK ;
Kuehnel, F ;
King, S ;
Fitzsimmons, WE .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (07) :855-864
[10]   A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation [J].
Magliocca, J. F. ;
Odorico, J. S. ;
Pirsch, J. D. ;
Becker, Y. T. ;
Knechtle, S. J. ;
Leverson, G. E. ;
Sollinger, H. W. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (08) :1702-1710